DDInter1247 DDInter1376
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Moxifloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Moxifloxacin {u} (Compound) binds {v} (Gene) TOP2A
Moxifloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Moxifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Moxifloxacin {u} (Compound) causes {v} (Side Effect) Oedema
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calcium acetate
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Moxifloxacin {u} may lead to a major life threatening interaction when taken with {v} Eribulin
Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Moxifloxacin (Compound) binds TOP2A (Gene)
Moxifloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Moxifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Moxifloxacin (Compound) causes Oedema (Side Effect)
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Moxifloxacin may lead to a major life threatening interaction when taken with Eribulin